Overall survival (OS) of sorafenib (So) plus interleukin-2 (IL-2) versus So alone in patients with treatment- naive metastatic renal cell carcinoma (mRCC): Final update of the ROSORC trial

被引：1
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Bracarda, Sergio
Ricci, Sergio
Ridolfi, Laura
Sacco, Cosimo
Miceli, Rosalba
Porta, Camillo
Bregni, Marco
Bajetta, Emilio
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Osped San Donato, Dept Oncol, USL 8, Arezzo, Italy
[3] Osped Santa Chiara, Pisa, Italy
[4] Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ San Matteo, Fdn IRCCS Policlin, Pavia, Italy
[7] Osped Busto Arsizio, Busto Arsizio, Italy
[8] Policlin Monza, Ist Oncol, Monza, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.356
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
356
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Survival advantage in patients treated with high-dose interleukin-2 (HDIL2) for metastatic renal cell carcinoma (mRCC)
    Lee, S.
    Baig, M.
    Rusciano, V.
    Gao, Y.
    Malik, S.
    Wiernik, P. H.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] The High-Dose Aldesleukin (HD IL-2) "Select'' Trial in Patients with Metastatic Renal Cell Carcinoma (mRCC)
    McDermott, D.
    Ghebremichael, M.
    Signoretti, S.
    Margolin, K.
    Clark, J.
    Sosman, J.
    Dutcher, J.
    Logan, T.
    Appleman, L.
    Atkins, M.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 903 - 904
  • [33] Results of a randomized, multicenter, phase III study of histamine dihydrochloride plus interleukin-2 (IL-2) versus IL-2 alone in patients (pts) with metastatic melanoma (MM).
    Agarwala, S
    Glaspy, J
    Whitman, E
    Kirkwood, J
    Hellstrand, K
    Gehlsen, K
    Wood, D
    Naredi, P
    Gonzalez, R
    ANNALS OF ONCOLOGY, 2000, 11 : 125 - 125
  • [34] The high-dose aldesleukin (HD IL-2) 'SELECT" trial in patients with metastatic renal cell carcinoma (mRCC)
    McDermott, D. F.
    Hebremichael, M. S.
    Signoretti, S.
    Margolin, K. A.
    Clark, J.
    Sosman, J. A.
    Dutcher, J. P.
    Logan, T.
    Figlin, R. A.
    Atkins, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [36] Activity of MVA 5T4 alone or in combination with either interleukin-2 (IL-2) or interferon-α (IFN) in patients (Pts) with metastatic renal cell cancer (MRCC)
    Cao, A.
    Hernandez-McClain, J.
    Willis, J.
    Harrop, R.
    Shingler, W.
    Chikoti, P.
    Drury, N.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [37] Phase II study of thalidomide, interleukin-2 (IL-2), and granulocyte macrophagecolony stimulating factor (GM-CSF) in patients (pts) with metastatic renal cell carcinoma (MRCC).
    Morgan, M
    Rawat, A
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 432S - 432S
  • [38] Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
    Vu, Peter
    Mai, Hanh P.
    Adams, William
    Gonzalez, Beverly
    Kliethermes, Stephanie
    Clark, Joseph
    Henry, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.
    Fishman, Mayer N.
    Clark, Joseph I.
    Alva, Ajjai Shivaram
    Curti, Brendan D.
    Agarwal, Neeraj
    Hauke, Ralph J.
    Mahoney, Kathleen Margaret
    Moon, Helen
    Treisman, Jonathan
    Tykodi, Scott
    Daniels, Gregory A.
    Morse, Michael
    Wong, Michael K. K.
    Kaufman, Howard
    Gregory, Nancy C.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Standard interleukin-2 (IL-2) and interferon-α immunotherapy versus an IL-2 and 4-Epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma
    Naglieri, E
    Gebbia, V
    Durini, E
    Lelli, G
    Abbate, I
    Selvaggi, FP
    Di Tonno, P
    Colucci, G
    ANTICANCER RESEARCH, 1998, 18 (3B) : 2021 - 2026
12345